Join our email list!

Get daily updates delivered to your inbox
Thank you for subscribing

MS News That Caught My Eye Last Week: Cure Connections, PIPE-307, Temelimab, EHP-101

MS News That Caught My Eye Last Week: Cure Connections, PIPE-307, Temelimab, EHP-101
4.4
(10)

NeurologyLive, CMSC Launch Expert Video Series ‘Cure Connections’

This series of 13 videos, designed for healthcare professionals, focuses on diagnosing MS, its psychological impact, managing symptoms, and treatments. Quality-of-life issues, fatigue, and patient support networks also will be discussed. I hope general neurologists will watch it, not just MS specialists, as many general neurologists seem out of touch with the ins and outs of diagnosing and treating multiple sclerosis. Just ask their patients.

NeurologyLive and the Consortium of Multiple Sclerosis Centers (CMSC) have launched a new video series called Cure Connections, designed to provide healthcare professionals with expert news and insights about multiple sclerosis (MS).

“These past several months our partnership with the CMSC has escalated to producing and disseminating extremely important education for neurology professionals everywhere,” Mike Hennessy Jr., president and CEO of MJH Life Sciences, NeurologyLive‘s parent company, said in a press release.

Click here to read the full story.

***

Pipeline Testing PIPE-307 Remyelinating Compound in Healthy Volunteers

Here’s a remyelination study being done on real people, not just mice. It’s only in Phase 1, meaning only safety is being tested, but it’s great news that this investigative treatment has moved out of the lab and into the clinic. Hopefully, Phase 2 won’t be too far down the road.

Pipeline Therapeutics has initiated a Phase 1 clinical trial to investigate PIPE-307, its lead treatment candidate for multiple sclerosis (MS), in healthy volunteers.

The trial (NCT04725175) will assess the compound’s safety, tolerability, and pharmacokinetics, or how the drug moves through the body. Up to 72 people, ages 18 to 55, will be enrolled at the trial’s single testing center in Western Australia. Recruitment is ongoing; more information can be found here.

Click here to read the full story.

***

Safety Board Says Phase 2 Temelimab Trial Should Move Forward

Getting the Phase 2 go-ahead from the Drug Safety Monitoring Board is temelimab, a monoclonal antibody that targets the viral protein pHERV-W. The hope is that temelimab will prevent that protein from activating the rogue immune response that damages myelin.

A Phase 2a clinical trial evaluating GeNeuro‘s investigational antibody temelimab as a treatment for relapsing multiple sclerosis (MS) should continue as planned, without modifications.

That’s the recommendation of a Drug Safety Monitoring Board, an independent committee of clinical research experts, which was evaluating the trial of the relapsing MS therapy candidate, the company announced in a press release.

Click here to read the full story.

***

Emerald Health Preparing for Phase 2 Trial of EHP-101 for Relapsing MS

EHP-101 is an oral medication whose goal is to reduce MS inflammation and promote remyelination. Its active ingredient is CBD, the non-hallucinogenic part of the cannabis plant.

Emerald Health Pharmaceuticals (EHP) is preparing for an international Phase 2 clinical trial testing EHP-101 for the treatment of multiple sclerosis (MS).

The study will take place in about 20 locations in the U.S. and Australia, and is expected to include approximately 50 patients with relapsing forms of MS — relapsing-remitting and relapsing secondary progressive MS. Enrollment is expected to begin later this year.

Click here to read the full story.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Diagnosed with MS at age 32 in 1980, Ed has written the “MS Wire” column for Multiple Sclerosis News Today since August 2016. He presents timely information on MS, blended with personal experiences. Before retiring from full-time work in 2012, Tobias spent more than four decades in broadcast and on-line newsrooms as a manager, reporter, and radio news anchor. He’s won several national broadcast awards. As an MS patient communicator, Ed consults with healthcare and social media companies. He’s the author of “We’re Not Drunk, We Have MS: A tool kit for people living with multiple sclerosis.” Ed and his wife split time between the Washington, D.C. suburbs and Florida’s Gulf Coast.
×
Diagnosed with MS at age 32 in 1980, Ed has written the “MS Wire” column for Multiple Sclerosis News Today since August 2016. He presents timely information on MS, blended with personal experiences. Before retiring from full-time work in 2012, Tobias spent more than four decades in broadcast and on-line newsrooms as a manager, reporter, and radio news anchor. He’s won several national broadcast awards. As an MS patient communicator, Ed consults with healthcare and social media companies. He’s the author of “We’re Not Drunk, We Have MS: A tool kit for people living with multiple sclerosis.” Ed and his wife split time between the Washington, D.C. suburbs and Florida’s Gulf Coast.

How useful was this post?

Click on a star to rate it!

Average rating 4.4 / 5. Vote count: 10

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *